Abstracts tagged "Randomized Trial"

Abstract Number: 0665 • ACR Convergence 2025
Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
Richard Furie¹, Teresa Baczkowska², Amit Saxena³, Imran Hassan⁴, Bongin Yoo⁵, Ben Lanza⁶, Himanshi Sehgal⁷, Frederic Boissard⁷, Jay Garg⁵, Thomas Schindler⁷, Elsa Martins⁷, William Pendergraft⁵ and Brad Rovin⁸, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸The Ohio State University, Columbus, OH
Background/Purpose: The REGENCY (NCT04221477) trial demonstrated superior efficacy of obinutuzumab and standard therapy (OBI+ST) over placebo and ST (PBO+ST) in patients (pts) with active lupus…
Abstract Number: 0555 • ACR Convergence 2025
Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Melinda J. Gooderham¹, Edward Lain², Robert Bissonnette³, Yu-Huei Huang⁴, Charles Lynde⁵, Matthias Hoffmann⁶, Joseph F Merola⁷, Eingun J. Song⁸, Jessica H. Rubens⁹, Amy M. DeLozier⁹, Ming-Chun Hsu⁹ and Richard B. Warren¹⁰, ¹SKiN Centre for Dermatology, Queen's University, & Probity Medical Research, Peterborough, ON, ON, Canada, ²Austin Institute for Clinical Research, Sanova Dermatology, Austin, TX, USA, Austin, TX, ³Innovaderm Research, Montreal, QC, Canada, Montreal, QC, ⁴Chang Gung Memorial Hospital & Chang Gung University, Taoyuan City, Taiwan, Taoyuan City, Taiwan (Republic of China), ⁵University of Toronto, Lynde Institute for Dermatology & Lynderm Research Inc, Markham, ON, Canada, ON, Canada, ⁶Dermatology Practice Dr. M Hoffmann, Witten, Germany, Witten, Germany, ⁷Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁸Frontier Derm, Mill Creek, WA, USA, WA, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁰Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose: Icotrokinra (ICO), a first-in-class, targeted oral peptide that binds and inhibits the interleukin (IL)-23R, was evaluated in ICONIC-TOTAL (NCT06095102).Methods: This Phase 3 trial included…
Abstract Number: 2587 • ACR Convergence 2025
Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
Puja Khanna¹, Amar Majjhoo², Rehan Azeem³, Ben Peace⁴, Bhavisha Desai⁵ and Vibeke Strand⁶, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Shores Rheumatology, St. Clair Shores, MI, ³Global MACD, Sobi Inc., Waltham, MA, ⁴Statistical Science, Sobi, Stockholm, Sweden, ⁵Sobi, Glastonbury, CT, ⁶Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Patients (pts) with uncontrolled gout (UG; persistent elevation in serum uric acid [sUA] levels and clinical manifestations despite oral urate-lowering therapy) have poor health-related…
Abstract Number: 1608 • ACR Convergence 2025
Efficacy of Anti-IL-5/R Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Christian Pagnoux⁸, Ulrich Specks⁹, Benjamin Terrier¹⁰, Lena Börjesson Sjö¹¹, Priya Jain¹², Aadarsh Lal¹³, Sofia Necander¹⁴, Claire Walton¹⁵ and Michael Wechsler¹⁶, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ⁹Mayo Clinic, Rochester, MN, ¹⁰Cochin Hospital, Paris, France, ¹¹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹³Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹⁴Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁵Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁶Department of Medicine, National Jewish Health, Denver
Background/Purpose: Results from the 1-year double-blind period and first year of the open-label extension (OLE) of the MANDARA trial (NCT04157348) demonstrated that over 60% of…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0874 • ACR Convergence 2025
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Atul Deodhar¹, Ricardo Blanco², Arthur Kavanaugh³, Alice Gottlieb⁴, Laura Coates⁵, Christopher Ritchlin⁶, Alan Kivitz⁷, Xiaofeng Zeng⁸, Akimichi Morita⁹, Diamant Thaçi¹⁰, Stefan Varga¹¹, Kexuan Li¹¹, Ying-Ming Jou¹², Eleni Vritzali¹³ and Philip J. Mease¹⁴, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³University of California, San Diego, School of Medicine, San Diego, CA, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁹Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol Myers Squibb, Boudry, Switzerland, ¹⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over…
Abstract Number: 2441 • ACR Convergence 2025
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Zahi Touma¹, Cynthia Aranow², Ioannis Parodis³, Rosalind Ramsey-Goldman⁴, Matthias Schneider⁵, Christine de La Loge⁶, Teri Jimenez⁷, Mina Nejati⁸ and Laurent arnaud⁹, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁶UCB, Brussels, Belgium, ⁷UCB, Raleigh, NC, ⁸Biogen, Cambridge, MA, ⁹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
Abstract Number: 1594 • ACR Convergence 2025
Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
Benjamin Terrier¹, David Jayne², Bernhard Hellmich³, Nancy Agmon-Levin⁴, Parameswaran Nair⁵, Lena Börjesson Sjö⁶, Priya Jain⁷, Aadarsh Lal⁸, Sofia Necander⁹, Claire Walton¹⁰, Peter Merkel¹¹ and Michael Wechsler¹², ¹Cochin Hospital, Paris, France, ²University of Cambridge, Cambridge, United Kingdom, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Clinical Immunology, Angioedema and Allergy, Sheba Medical Center, Ramat Gan, Israel, ⁵Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ⁹Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Department of Medicine, National Jewish Health, Denver
Background/Purpose: The MANDARA trial (NCT04157348) demonstrated that after two years of anti-interleukin-5/receptor (anti-IL-5/R) therapy over 60% of patients with relapsing or refractory eosinophilic granulomatosis with…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0814 • ACR Convergence 2025
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Annie Brink¹, Johan Karlsson Wallman², Jon T Einarsson¹, Meliha Kapetanovic¹, Elisabeth Mogard¹, Elisabet Lindqvist¹, Carmen Roseman¹, Kristina Lend³, Merete Hetland⁴, Mikkel Ostergaard⁵, Kim Horslev-Petersen⁶, Dan Nordstrom⁷, Tuulikki Sokka-isler⁸, Bjorn Gudbjornsson⁹, Gerður María Gröndal⁹, Marte Heiberg¹⁰, Espen Haavardsholm¹⁰, Michael Nurmohamed¹¹, Anna Rudin¹², Ronald van Vollenhoven¹³, Till Uhlig¹⁰, Jon Lampa¹⁴ and Tor Olofsson², ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ³Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ⁶Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁸Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, ⁹Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹¹Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁴Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
Abstract Number: 2429 • ACR Convergence 2025
mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
Shanthini Kasturi¹, Erin Morrissey¹, Anna Deck², Nina Gulati², Zoe Gilbard², Kiran Singh¹, Monique Gore-Massy³, Faye Chiu⁴, Priscilla Calvache⁵, Jillian Rose-Smith⁵, Andre Ogura⁶, Lucas Ogura Dantas⁶, Wambui Machua⁷, Julia Nguyen⁸, Lisa Mandl⁵, Hocine Tighiouart¹, Ludovic Trinquart², Iris Navarro-Millan⁹ and Sara Folta¹⁰, ¹Tufts Medical Center, Boston, MA, ²Tufts University School of Medicine, Boston, MA, ³N/A, West Orange, NJ, ⁴N/A, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Ambulomics, Arlington, MA, ⁷Piedmont Healthcare, Atlanta, GA, ⁸Hospital for Special Surgery, New York, ⁹Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ¹⁰Tufts Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is a highly prevalent and debilitating symptom affecting up to 90% of individuals living with systemic lupus erythematosus (SLE). Despite its significant impact,…
Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Susan Manzi¹, Ian Bruce², Eric Morand³, Richard Furie⁴, Yoshiya Tanaka⁵, Patricia Puzio⁶, Emon Khan⁷, Jenny Wissmar⁸, Michael Song⁹ and Catharina Lindholm¹⁰, ¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁴Division of Rheumatology, Northwell Health, Great Neck, NY, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, ¹⁰BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
Abstract Number: 0657 • ACR Convergence 2025
Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
FNU Ruchi¹, Ioana Coman¹, Bryan Blaker¹, Lucero Blaker¹, Joy Park², Jorge Cabezas¹, Dilip Rao¹, +Xiaojing Wang¹, Aparna Godavarthy¹, Marlene Marte Furment³, Sandy Nasr⁴, Sravani Lokineni⁵, Christina Donath⁴, SARA KAHLOWN⁶, Damira Sereda¹, Binod Kc¹, Ilya Ivyanskiy¹, Bhavya Poudyal⁷, Arthur Weinstein⁸, Rosalind Ramsey-Goldman⁹, Michael Weisman¹⁰, Cynthia Aranow¹¹, Mariko Ishimori¹⁰, Kyriakos Kirou¹², Jihad Ben Gabr¹³, Sheetal Rayancha¹⁴, Nancy Olsen¹⁵, Fotios Koumpouras¹⁶, Judith Lin¹⁷, Stephen Faraone¹, Daniel Wallace¹⁸, Michael McDermott¹⁹ and Andras Perl²⁰, ¹SUNY Upstate Medical University, Syracuse, NY, ²Upstate Medical University, Syracuse, NY, ³Medical Affiliates of Cape Cod, Hyannis, MA, ⁴SUNY Upstate University Hospital, Syracuse, NY, ⁵Deaconess Hospital, Evansville, IN, ⁶Suny upstate medical university, Camillus, NY, ⁷SUNY Upstate Medical University, Cicero, NY, ⁸retired from clinical practice, volunteer academic faculty, Claremont, CA, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Cedars-Sinai Medical Center, LOS ANGELES, CA, ¹¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Hospital for Special Surgery, New York, NY, ¹³Division of Rheumatology & Clinical Immunology, SUNY Upstate Medical University, Syracuse, NY, ¹⁴SUNY Upstate Medical University, Jamesville, NY, ¹⁵Penn State University/Milton S Hershey, Hershey, PA, ¹⁶Yale School of Medicine, New Haven, CT, ¹⁷Ohio State University Wexner Medical Center, Columbus, OH, ¹⁸Cedars Sinai Medical Center, Studio City, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in 5 years. The major causes of death…
Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Eric Morand¹, Victoria Werth², Richard Furie³, Sanjeev Roy⁴, Ruth Fernandez Ruiz⁵, Summer Goodson⁶, Hans Gühring⁷, Flavie Moreau⁶ and David Pearson⁸, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Ares Trading SA, an affiliate of Merck KGaA, Darmstadt, Germany, Eysins, Switzerland, ⁵EMD Serono, Billerica, PA, ⁶EMD Serono, Billerica, MA, ⁷The healthcare business of Merck KGaA, Darmstadt, Germany, ⁸Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…
Abstract Number: 2368 • ACR Convergence 2025
Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease¹, Christopher Ritchlin², Laura Coates³, Alexa P. Kollmeier⁴, Bei Zhou⁵, Yusang Jiang⁵, Karen Bensley⁵, Koeun Im⁶, Rattandeep Batra⁷, Soumya Chakravarty⁸, Proton Rahman⁹ and Désirée Van Der Heijde¹⁰, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²University of Rochester Medical Center, Canandaigua, NY, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁶Johnson & Johnson, Cambridge, MA, USA, Cambridge, MA, ⁷Johnson & Johnson, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁹Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with active psoriatic arthritis (PsA) are at risk of irreversible joint damage that may significantly impact quality of life. Guselkumab (GUS), a fully…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].